Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Expanded Access Treatment of Neladalkib (NVL-655) in Patients With Advanced ALK+ NSCLC or Other ALK+ Solid Tumors

NCT06834074 is registered in ClinicalTrials.gov with Nuvalent Inc. as lead sponsor.

NCT NCT06834074
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06834074 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Expanded Access Treatment of Neladalkib (NVL-655) in Patients With Advanced ALK+ NSCLC or Other ALK+ Solid Tumors
Lead sponsor
Nuvalent Inc.
Phase
Expanded access
Overall status
Available
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

alk-positive non-small cell lung cancer (nsclc), non small cell lung cancer